Texas Public Radio: New Alzheimer’s drug will be available to San Antonio patients but is not suitable for all
Posted on: Friday, July 12th, 2024
The Biggs Institute for Alzheimer’s and Neurodegenerative Diseases at UT Health San Antonio will soon offer Alzheimer’s and mild cognitive impairment patients the new FDA-approved medication, donanemab, to slow cognitive decline. However, the cost and the drug being administered intravenously means it may not be easily accessible for all patients.
Sudha Seshadri, MD, director of the Biggs Institute, says providing patients access to clinical trials like AHEAD 3-45, which offers similar treatment options, can be a solution to increasing patient access to innovative treatments.
Read the full article at TPR.org.